Primary Insomnia Clinical Trial
Official title:
Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties: a 6-week, Randomized, Double-blind, Placebo-controlled, Polysomnography Study.
Primary objective:
- To assess the efficacy of eplivanserin 5mg/day in comparison to placebo after 6 weeks of
treatment on sleep maintenance of insomniac patients, as measured by Polysomnography Wake
Time After Sleep Onset (PSG-WASO) and Polysomnography Number of Awakenings (PSG-NAW).
Secondary objectives:
- To evaluate the effects of eplivanserin 5mg/day as compared to placebo after 6 weeks of
treatment on other sleep parameters measured by PSG recordings (Total Sleep Time -
PSG-TST, Sleep Efficiency - PSG-SE, Latency to Persistent Sleep - PSG-LPS) and reported
by patients (Wake Time After Sleep Onset - pr-WASO, Number of Awakenings - pr-NAW,
Total Sleep Time - pr-TST, Quality of Sleep - QoS and Refreshing Quality of Sleep -
RqoS).
- To evaluate the effects of eplivanserin 5mg/day on sleep architecture compared to
placebo.
- To evaluate the effect of eplivanserin 5mg/day on daytime functioning using the Sleep
Impact Scale (SIS), as compared with placebo after 6 weeks of treatment.
- To evaluate patient's impression of treatment effects using the Patient's Global
Impression questionnaire.
- To evaluate the potential for next-day residual effects (using patient's morning
questionnaire and psychometric tests) with eplivanserin 5mg/day as compared to placebo.
- To evaluate the potential for rebound insomnia following abrupt discontinuation of
eplivanserin 5mg/day in comparison with placebo.
- To evaluate the effect of eplivanserin, compared to placebo, on the quality of life of
patients with primary insomnia using the SF-36 Health Survey.
- To evaluate the clinical safety and tolerability of eplivanserin 5mg/day compared to
placebo.
Randomized, double-blind, placebo, controlled study with 2 parallel groups Duration of
treatment : 6 weeks
Duration of observation: 9 weeks
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03461666 -
Comparison of Efficacy of Behavioral Approaches for Treatment of Insomnia
|
N/A | |
| Recruiting |
NCT02243501 -
Better Nights, Better Days for Typically Developing Children
|
N/A | |
| Completed |
NCT01636791 -
CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care
|
Phase 3 | |
| Completed |
NCT00770510 -
A Phase II/III Study of SEP-190 (Eszopiclone) in Patients With Primary Insomnia (Study 190-126)
|
Phase 2/Phase 3 | |
| Completed |
NCT00520832 -
A Pilot Study Of The Effects Of Microcurrent On Three Sleep Surveys
|
Phase 2 | |
| Recruiting |
NCT00415714 -
Safety and Efficacy of an Ambulatory Biofeedback Device for Primary Insomnia
|
N/A | |
| Terminated |
NCT00420810 -
Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED)
|
Phase 3 | |
| Completed |
NCT00178048 -
Paroxetine in the Treatment of Chronic Primary Insomnia
|
Phase 4 | |
| Completed |
NCT00816673 -
Sleep Inducing And Maintaining Efficacy Of Circadin In Elderly Insomniacs
|
Phase 2 | |
| Completed |
NCT01960452 -
A High Density EEG Comparison of Sleep Patterns in Insomnia
|
N/A | |
| Completed |
NCT01957111 -
Metabolomics of Insomnia-Related Hyperarousal
|
N/A | |
| Completed |
NCT01181232 -
A Study to Compare Efficacy and Safety of Zolpidem Modified Release Formulation Versus Zolpidem in Insomnia Patients
|
Phase 4 | |
| Completed |
NCT00784875 -
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
|
Phase 2 | |
| Completed |
NCT00551148 -
A Dose-ranging, Multicenter Polysomnography Trial of PD 0200390 in Adults With Primary Insomnia
|
Phase 2 | |
| Completed |
NCT00397189 -
Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients
|
Phase 3 | |
| Completed |
NCT00352144 -
6-Month Chronic Efficacy & Safety Study of Eszopiclone in Adult Subjects With Primary Insomnia
|
Phase 3 | |
| Completed |
NCT02290405 -
Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
|
||
| Completed |
NCT03314441 -
Effects of Regular Practice of Yoga on Subjective and Objective Sleep Quality in Primary Insomnia
|
N/A | |
| Completed |
NCT00792298 -
Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006)
|
Phase 2 | |
| Completed |
NCT01021852 -
Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)
|
Phase 2 |